Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Off-Label Practices Plague Circulatory System Device Randomized Trials

This article was originally published in The Gray Sheet

Executive Summary

Off-label use of biliary stents is hindering superficial femoral artery (SFA) device development, CDRH Division of Cardiovascular Devices Director Bram Zuckerman told participants at CRT 2004 in Washington, D.C
Advertisement

Related Content

Current, Former FDA Circ Panel Chairs Stress Need For Data On PFO Devices
Current, Former FDA Circ Panel Chairs Stress Need For Data On PFO Devices
FDA Expects Wide Range Of Peripheral Drug-Eluting Stent Applications
FDA Expects Wide Range Of Peripheral Drug-Eluting Stent Applications
J&J biliary stent recall
J&J Precise Panel Vote Nearly Split On Carotid Disease Subgroup Benefit
PFO Occluder Erosion, Post-Implant Thrombosis Indicate Caution Warranted
FDA Defers To Expert Panel For Peripheral DES Guidance Development
Peripheral Stent Study Design Panel, Endpoint Data Development Urged
Advertisement
UsernamePublicRestriction

Register

MT020243

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel